Latest News and Press Releases

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028" has been added to ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030" has been added to ResearchAndMarkets.com's offering. ...

Dublin, April 21, 2025 (GLOBE NEWSWIRE) -- The "Gastric Neuroendocrine Tumors Market" report has been added to ResearchAndMarkets.com's offering. The gastric neuroendocrine tumor (gNET) market,...

Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The "Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028" report has been added to ...

Dublin, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The "Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's...

New York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight  The launch of upcoming...

Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "Global Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of...

Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177), Route of Administration (Intravenous, Oral), End User,...

Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.

New York, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is slated to expand at ~6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10...